Business
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress
Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the
About this update from Curis, Inc.
[{"type":"text","content":"Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker\nIRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response to emavusertib\nPromising clinical and preclinical analysis showcases the potential of emavusertib in treating pCNSL\nLEXINGTON, Mass., June 10, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the presentation of novel findings on biomarker development for IRAK4 inhibitor emavusertib, collaborative work from the University of Florida in primary CNS lymphoma (pCNSL), and clinical data from the TakeAim Leukemia and TakeAim Lymphoma studies at the 2022 European Hematology Association (EHA) Hybrid Congress currently taking place in Vienna, Austria and online until June 12, 2022.\n\n \n \n \n \n \n \n\n \n\"We are delighted to share with our colleagues in Europe our findings regarding IRAK4's previously undescribed localization in the nucleus of cancer cells. It appears that when IRAK4 is found in the nucleus with active NF-kB proteins p50 and p65, using a technique which we refer to as 'triple staining,' this triple nuclear presence is associated with better responses to emavusertib,\" said James Dentzer, President and Chief Executive Officer of Curis.\n\"Also at EHA this year, collaborative work by Dr. Duane Mitchell's team at the University of Florida is being presented on the potential role of emavusertib in treating pCNSL, including data on one patient who achieved a complete response following previous treatment with ibrutinib,\" Mr. Dentzer continued. \"And finally, in addition to this foundational work on IRAK4 biology, we are presenting data from our TakeAim Lymphoma and TakeAim Leukemia studies as we continue to spread the word on IRAK4 and the utility of inhibiting this important target to our European colleagues.\"\nCuris scientists have discovered previously unknown nuclear accumulation of IRAK4 selectively in acute myeloid leukemia (AML) cells whereas nuclear IRAK4 was not detectable in mature myeloid cells (#2609). IRAK4 nuclear accumulation is significantly correlated with NF-kB activation in bone marrow samples from de novo AML patients and in AML cell lines. The detection of IRAK4 and NF-kB (phospho-...